På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Kaya Plewnia, hjælp af denne formular.

14 Aug 2014

Det amerikanske Defense Threat Reduction Agency vil støtte præklinisk udvikling af Evolva lægemiddel

Evolva has entered into a contract (HDTRA1-14-C-0122) with the US Defense Threat Reduction Agency (DTRA) for the program “GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents”. DTRA will fund USD 6.5 million for the first 15-month stage and up to an additional USD 8.6 million if the two remaining stages (2 years) are executed.

Evolva continues to pursue options to partner its pharmaceutical pipeline in line with its strategy of focusing on high value ingredients for health, wellness and nutrition.

If you can't find it here or have feedback to our website, please do not hesitate to contact me on kp@danskbiotek.dk or 28895854

Copyright 2014 Danskbiotek. All rights reserved.